Chemotherapy

Factors That Determine Sequence of Administration for Multiple Chemotherapeutic Agents

Factors That Determine Sequence of Administration for Multiple Chemotherapeutic Agents

By

Chemotherapy agents are sometimes required to be administered in a specific sequence. What factors influence the need to follow a specific sequence?

Mimicking Fasting During Chemotherapy Enhances T Cell Activity in Preclinical Study

By

Fasting during chemotherapy treatment may increase the presence of cancer-killing T cells, according to recent study data.

Understanding a Molecular Switch Modulating Tumor Metastasis and Chemotherapy Resistance

By

Dab2 is an endocytic adaptor and tumor suppressor whose expression occurs during the epithelial-mesenchymal transition, which is mediated by TGF-beta. This study sought to understand how Dab2 regulates apoptosis.

Telomere Length Predicts Risk for Delayed Recovery in Pediatric Patients With AML

Telomere Length Predicts Risk for Delayed Recovery in Pediatric Patients With AML

By

Telomere length is predictive for determining which children treated for AML are at highest risk for delayed recovery, a finding that may have significant implications for treatment-related morbidity and mortality.

Tango Dancing Improves Balance and Fall Risk in Cancer Patients With Peripheral Neuropathy

Tango Dancing Improves Balance and Fall Risk in Cancer Patients With Peripheral Neuropathy

By

Balanced is improved and fall risk is reduced among cancer patients with peripheral neuropathy who participated in Argentine tango dancing as a form of therapy.

Triplet Regimen Followed by Maintenance Active in Triple-negative Breast Cancer

Triplet Regimen Followed by Maintenance Active in Triple-negative Breast Cancer

By

A first-line triplet chemoimmunotherapy regimen comprised of paclitaxel, capecitabine, and bevacizumab followed by capecitabine and bevacizumab alone as maintenance therapy is highly active with a manageable safety profile in patients with triple-negative breast cancer.

PET-CT Can Inform Decision to Omit Bleomycin in Hodgkin Lymphoma Treatment to Reduce Toxicity

PET-CT Can Inform Decision to Omit Bleomycin in Hodgkin Lymphoma Treatment to Reduce Toxicity

By

Omitting bleomycin from the treatment regimen for Hodgkin lymphoma in patients with negative findings on an interim PET scan led to a lower incidence of pulmonary toxic effects without significantly lowering treatment efficacy.

Flushing the Line Between Medications in IV Administrations of Multiple Agents

Flushing the Line Between Medications in IV Administrations of Multiple Agents

By

What factors should be considered when calculating an adequate postmedication flush to deliver complete, accurate doses of small-volume IV medications to our patients?

Novel Nanoparticle Achieves Concomitant Tumor Cell Death and Resistance Suppression

By

Resistance to therapy through adaptation poses a major hurdle for cancer therapy. Bioengineers addressed this by creating a single nanoparticle that comprises a synergistic drug pair that shuts down mechanisms of resistance to a degree that has not been previously achieved.

Chemotherapy Boosts Effectiveness of Immunotherapy in the Treatment of Ovarian Cancer

Chemotherapy Boosts Effectiveness of Immunotherapy in the Treatment of Ovarian Cancer

By

Immunotherapy for advanced ovarian cancer more effectively treats tumors when administered immediately after chemotherapy. Sequential chemoimmunotherapy could improve disease control in stage IIIC/IV tubo-ovarian HGSC.

Assessment and Monitoring of Patients Receiving Chemotherapy for Multiple Myeloma: Strategies to Improve Outcomes

Assessment and Monitoring of Patients Receiving Chemotherapy for Multiple Myeloma: Strategies to Improve Outcomes

[Blood and Lymphatic Cancer: Targets and Therapy] This research reviews updates in the diagnosis and management of multiple myeloma, and provides for assessment and monitoring strategies for patients receiving chemotherapy for multiple myeloma.

Dronabinol for Chemotherapy-induced Nausea and Vomiting Unresponsive to Antiemetics

Dronabinol for Chemotherapy-induced Nausea and Vomiting Unresponsive to Antiemetics

[Cancer Management and Research] This review focuses on dronabinol and its role in the treatment of chemotherapy-induced nausea and vomiting (CINV).

Adjuvant Chemotherapy Improves Overall Survival in Early Stage NSCLC

By

Adjuvant chemotherapy in patients with stage Ib non-small cell lung cancer improved overall survival and 5-year overall survival.

Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness

Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness

By

Aligning chemotherapy administration to the time of day when the body is most awake benefits the effectiveness of the treatment, as shown in a mouse model.

Novel Device Captures Excess Chemotherapy, Avoiding Systemic Exposure to the Drugs

Novel Device Captures Excess Chemotherapy, Avoiding Systemic Exposure to the Drugs

By

A new material was developed to soak up chemotherapy drugs after the tumor is treated and before they can circulate throughout the body, potentially limiting the side effects of chemotherapy.

Outcomes Are Not Improved With Pegylated Interferon Alpha-2a vs Interferon Alpha-2a

Outcomes Are Not Improved With Pegylated Interferon Alpha-2a vs Interferon Alpha-2a

By

PEG-IFN did not improve improve outcomes for patients with melanoma compared with IFN. Furthermore, patients receiving PEG-IFN were more likely to discontinue treatment due to toxicity.

Adjuvant Chemotherapy Improves Survival in Stage IB NSCLC

Adjuvant Chemotherapy Improves Survival in Stage IB NSCLC

By

In patients with completely resected stage IB NSCLC, adjuvant chemotherapy is associated with improved survival regardless of tumor size.

Novel Approach Uses Ultrasound to Enhance Efficacy of Chemotherapy in Pancreatic Cancer

Novel Approach Uses Ultrasound to Enhance Efficacy of Chemotherapy in Pancreatic Cancer

By

Combining a laboratory ultrasound technique called sonoporation with the commercially available chemotherapy compound gemcitabine increases the porosity of pancreatic cells with microbubbles and helps get the drug into cancer cells.

Chemotherapy and Radiation Prior to Surgery Improves Outcomes in Patients With Pancreatic Cancer

Chemotherapy and Radiation Prior to Surgery Improves Outcomes in Patients With Pancreatic Cancer

By

Despite the increased risk, patients whose pancreatic cancer tumor has grown to encompass critical blood vessels can be candidates for surgery. Data on efforts to fine-tune a protocol for these patients were presented at the SSAT 57th Annual Meeting.

Potential Survival Advantage Observed for 177Lu-Dotatate in Midgut Neuroendocrine Tumors

Potential Survival Advantage Observed for 177Lu-Dotatate in Midgut Neuroendocrine Tumors

By

NETTER-1 trial results of the somatostatin analogue peptide, 177Lu-DOTA0-Tyr3-octreotate (177Lu-Dotatate), suggest a potential survival benefit in patients with advanced midgut neuroendocrine tumors (NETs), attendees at the ASCO 2016 Annual Meeting were told.

Adding Doxorubicin to Sorafenib Does Not Improve Overall Survival in Hepatocellular Carcinoma

Adding Doxorubicin to Sorafenib Does Not Improve Overall Survival in Hepatocellular Carcinoma

By

In patients with advanced hepatocellular carcinoma (HCC), adding doxorubicin to sorafenib did not improve overall survival or progression-free survival and resulted in higher toxicity compared to sorafenib alone, results from a phase 3 study presented at the ASCO 2016 Annual Meeting have shown.

No Benefit for Chemoradiotherapy vs Chemotherapy After Resectable Gastric Cancer

No Benefit for Chemoradiotherapy vs Chemotherapy After Resectable Gastric Cancer

By

First results from the phase 3 CRITICS study found no significant difference in overall survival between postoperative chemotherapy and chemoradiotherapy in patients with resectable gastric cancer, according to a study presented at the ASCO 2016 Annual Meeting.

Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple Myeloma

Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple Myeloma

By

Adding daratumumab to bortezomib and dexamethasone was associated with a 61% reduction in risk of disease progression in patients with relapsed or refractory multiple myeloma (RRMM), according to results of the phase 3 CASTOR study presented in a plenary session at the ASCO 2016 Annual Meeting.

Adding Temozolomide to Radiotherapy Improves Survival in Elderly Patients With Newly Diagnosed Glioblastoma

Adding Temozolomide to Radiotherapy Improves Survival in Elderly Patients With Newly Diagnosed Glioblastoma

By

The addition of temozolomide to standard short-course radiation therapy significantly improved both overall and progression-free survival in elderly patients with newly diagnosed glioblastoma, results from the first study to test this combination in this age group concluded in a plenary presentation at the ASCO 2016 Annual Meeting.

Alemtuzumab + CHOP for Peripheral T Cell Lymphoma: Higher Remission, But Not Survival

Alemtuzumab + CHOP for Peripheral T Cell Lymphoma: Higher Remission, But Not Survival

By

When added to the CHOP regimen, alemtuzumab increases remission rates in elderly patients with peripheral T cell lymphoma, final analysis of the international ACT-2 phase 3 trial presented at the ASCO 2016 Annual Meeting has shown.

Concurrent Chemoradiotherapy Remains Standard of Care in Locally Advanced SCCHN

Concurrent Chemoradiotherapy Remains Standard of Care in Locally Advanced SCCHN

By

A phase 3 noninferiority study has found that in patients with nonoperable locally advanced squamous cell cancer of the head and neck, concurrent chemoradiotherapy remains the standard treatment, according to results presented at the ASCO 2016 Annual Meeting.

Utidelone Plus Capecitabine Active in Patients Heavily Pretreated for Metastatic Breast Cancer

Utidelone Plus Capecitabine Active in Patients Heavily Pretreated for Metastatic Breast Cancer

By

The genetically engineered epothilone analog, utidelone, in combination with capecitabine significantly improved progression-free survival and objective response rates in patients with metastatic breast cancer who were heavily pretreated, compared with capecitabine alone, results of a phase 3 trial presented at the 2016 ASCO Annual Meeting have shown.

Tailored Dose-Dense Chemotherapy Improves Event-free Survival in High-Risk Breast Cancer

Tailored Dose-Dense Chemotherapy Improves Event-free Survival in High-Risk Breast Cancer

By

Tailored dose-dense chemotherapy significantly improved event-free survival and also showed efficacy in relapse-free and overall survival compared with standard adjuvant chemotherapy in patients with high-risk breast cancer, according to results of the phase 3 PANTHER study reported at the 2016 ASCO Annual Meeting.

Anthracycline-based Regimens Superior in Treating High-Risk, HER2-negative Breast Cancer

Anthracycline-based Regimens Superior in Treating High-Risk, HER2-negative Breast Cancer

By

Interim joint analysis of the ABC Trials showed invasive disease-free survival was significant for superiority of anthracycline/taxane-based chemotherapy regimens (TaxAC) relative to docetaxel plus cyclophosphamide, according to study results presented at the 2016 ASCO Annual Meeting.

Study Supports Increased Role for Surgery in Multimodality Therapy for Early Stage SCLC

Study Supports Increased Role for Surgery in Multimodality Therapy for Early Stage SCLC

By

Surgery for early stage small cell lung cancer (SCLC) is rarely used. However, results from a population-based database has shown surgery with adjuvant chemotherapy with or without radiation for node-negative SCLC was associated with better survival compared with concurrent chemoradiation, according to a presentation at the 2016 ASCO Annual Meeting.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs